Desvenlafaxine Tablet, Extended Release
Product Images NDC 63304-192

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 63304-192). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30's Bottle Pack (Desvenlafaxine 100mg)

Label for Desvenlafaxine extended-release tablets, 100 mg strength, manufactured by Alembic Pharmaceuticals and distributed by Sun Pharmaceutical Industries, Inc. The label indicates a package count of 30 tablets and includes storage instructions, dispensing information, and a barcode. The label also notes the product is Rx only and sealed for protection.*

FDA Label Image

30's Bottle Pack (Desvenlafaxine 50mg)

Desvenlafaxine extended-release tablets 50 mg oral dosage form packaging label. The label shows the product name, strength, and dosage form along with instructions for storage and dispensing. It is distributed by Sun Pharmaceutical Industries, Inc. and manufactured by Alembic Pharmaceuticals Limited, with a pack count of 30 tablets. The label includes a barcode and a note for pharmacists to dispense the accompanying Medication Guide.*

FDA Label Image

Desvenlafaxine Figur4

A line graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph compares Desvenlafaxine Extended-Release Tablets 50 mg to placebo, with a solid line representing Desvenlafaxine and a dashed line representing placebo. The placebo group shows a higher proportion of relapse over time.*

FDA Label Image

Desvenlafaxine Figur5

A Kaplan-Meier survival curve graph showing the estimated proportion of patients with relapse (%) over time (days from randomization). Two lines compare Desvenlafaxine Extended-Release Tablets and placebo in terms of time to relapse in patients. The vertical axis represents the percentage of patients with relapse, and the horizontal axis represents days since randomization.*

FDA Label Image

Desvenlafaxine Figure1

A forest plot chart presenting geometric mean ratios (90% confidence intervals) for Cmax and AUC parameters of Desvenlafaxine in populations with varying degrees of renal and hepatic impairment and different demographic groups. The x-axis represents change relative to reference, with data points and error bars indicating variability across mild, moderate, severe renal and hepatic impairment, ESRD, gender, and age groups above 65 years.*

FDA Label Image

Desvenlafaxine Figure2

A forest plot chart showing the geometric mean ratio with 90% confidence intervals for changes in pharmacokinetic parameters Cmax and AUC of desvenlafaxine when coadministered with the CYP3A4 inhibitor ketoconazole. The x-axis represents the change relative to a reference ranging from 0.5 to 2.0.*

FDA Label Image

Desvenlafaxine Figure3

A forest plot chart depicting geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC) of drugs interacting with Desvenlafaxine at various doses. The chart compares changes relative to reference values for Desipramine, Midazolam, Tamoxifen, and Aripiprazole with Desvenlafaxine 50 mg, 100 mg, and 400 mg doses. Data points indicate whether the values are above, near, or below the reference line.*

FDA Label Image

Structure (Desvenlafaxine Str)

Chemical structure diagram of desvenlafaxine, the active ingredient in the extended-release tablets. The diagram shows the molecular structure with hydroxyl, methyl, and cyclohexane groups clearly illustrated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.